|

DRP-104 Clinical Trials

2 actively recruiting trials across 2 locations

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
  • NYU Langone Health1

Indications

  • Cancer2
  • Fibrolamellar Hepatocellular Carcinoma1
  • Lung Cancer1
  • Non Small Cell Lung Cancer1

Baltimore, Maryland1 trial

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Johns Hopkins SKCCC

Phase 1/2

New York, New York1 trial

DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer

NYU Langone Health

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.